Investment bank raises guidance for Novo Nordisk after "impressive" Wegovy launch

An "impressive" launch of Novo Nordisk's new obesity treatment Wegovy has led US investment group Jefferies to increase its expectations for the Danish pharmaceutical company.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR

Novo Nordisk's share price target has been increased from USD 66 (DKK 415) to USD 74 (DKK 465) by US investment bank Jeffries after an "impressive" launch, the bank reports.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading